An agency of the European Union
Frequent searches:
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 13 - 17 July 2026, and includes updates on Ebola, respiratory virus epidemiology, swine influenza A(H3N2), Influenza A(H5), Vibrio, West Nile virus infections, Crimean-Congo haemorrhagic fever (CCHF), expert deployments, Influenza A(H5N1), cyclosporiasis, World Pride, and mpox.
Communicable disease threats report, 13 - 17 July 2026, week 29
English (5.04 MB - PDF)
Weekly update with the latest reports on West Nile virus cases in Europe.
Overview of EU/EEA countries and areas with reported CCHF cases in 2026.
Since 2022, an increasing number of European countries have reported cases of gonorrhoea caused by ceftriaxone-resistant Neisseria gonorrhoeae, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Upsurge in ceftriaxone-resistant Neisseria gonorrhoeae with evidence of domestic transmission in the EU/EEA and the UK
English (328.45 KB - PDF)
An increasing number of European countries have detected gonococcal strains resistant to the antibiotic ceftriaxone, the first-line drug to treat gonorrhoea infection.
This list below shows the current accommodation sites in EU/EEA countries with which clusters of Legionnaires’ disease have been identified but where the European Legionnaires’ disease Surveillance Network (ELDSNet) is unable to assess the risk of Legionella infection, or where ELDSNet believe there may be increased risk to travellers.
This page includes the selection committees that have been appointed for the ongoing selection procedures.
This report presents a description of COVID-19 vaccine coverage in the EU/EEA between 1 August 2025 and 27 March 2026, with some variation in reporting dates between countries.
COVID-19 vaccination coverage in the EU/EEA during the 2025–26 season campaigns.pdf
English (1.11 MB - PDF)
This report reviews the progress made between 2019 and 2023 and monitors the effectiveness of the 2019 Response Plan.
Response plan to control and manage the threat of multi-and extensively drug-resistant gonorrhoea in Europe
English (4.96 MB - PDF)ECDC highlights the importance of communicating clear messages on doxy‑PEP, while acknowledging that doxy‑PEP can be effective at reducing syphilis and chlamydia at the individual level, it does not recommend it as a population‑level intervention.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 6 - 10 July 2026, and includes updates on Ebola, West Nile Virus infections, Crimean-Congo haemorrhagic fever, Vibrio, Influenza A (H9N2), expert deployment, and an overview of respiratory virus epidemiology in the EU/EEA.
Communicable disease threats report, 6 - 10 July 2026, week 28
English (3.76 MB - PDF)
This operational checklist presents an overview of health preparedness and response planning elements for the potential importation of a case of Ebola disease into a European Union/European Economic Area (EU/EEA) Member State health system.
Preparedness and response for imported cases of Ebola disease into an EU/EEA country - Updated 10 July 2026
English (1.28 MB - PDF)
This case definition aims to classify Ebola disease cases for epidemiological purpose and relies on clinical, epidemiological, laboratory and high-risk exposure criteria.
This disease surveillance report presents an overview of the epidemiological situation for communicable diseases and related health issues that are under European Union (EU) and European Economic Area (EEA) surveillance.
Microbiology laboratories are a first line of defence against health threats from communicable diseases.
In 2023, 12 EU Member States and one EEA country reported 6 254 SSIs from a total of 421 397 surgical procedures for nine types of surgical procedures.
Healthcare-associated infections: surgical site infections - Annual Epidemiological Report for 2023
English (1.31 MB - PDF)
Dashboard showing the countries that still have remaining cases of WPV, and also those with cases of circulating vaccine derived polio virus (cVPDV).